



Centre de Recherche des Cordeliers

5th edition

PROVISIONAL PROGRAM

15 rue de l'École de Médecine 75006 Paris, France

Tuesday September 14th 2021

PRIMER ON CANCER IMMUNOLOGY,
RADIATIONS, DNA DAMAGE
AND IMMUNOTHERAPY



Society for Immunotherapy of Cancer

13.25-13.30 pm OPENING

Welcome and introduction: Pr Eric Deutsch, Head of Gustave Roussy Radiation Oncology Department, FR / conference co-chair

PRIMER ON CANCER IMMUNOLOGY, RADIATIONS, DNA DAMAGE AND IMMUNOTHERAPY
(Educational Session CME accredited in partnership with SITC)

13.30-15.30 Part I

Cancer Immunology and Immunotherapy

(chair: Eric Deutsch and Alexandre Bobard)

🕒 13.30 -14.00

Tumor infiltrating adaptive immunity in cancer immunology and therapeutics

Pr Catherine Sautes Fridmans, Cordeliers Research Center 

🕒 14.00 -14.30

Microbiota-Centered Interventions : data and prospects

Dr Lisa Derosa, Gustave Roussy 

🕒 14.30 -15.00

Beneficial autoimmunity dictates the prognosis of cancer therapy

Pr Guido Kroemer, Cordeliers Research Center 

🕒 15.00 -15.30

Clinical immunotherapy in melanoma

Pr Caroline Robert, Gustave Roussy 

15.30-16.00 **Coffee break**


16.00-18.00 Part II

Radiations, DNA Damage and Cancer Immunotherapy

(chair: Hervé Fridman and François-Xavier Danlos)

🕒 16.00 -16.30

Exploiting the replication stress-inflammation axis for cancer therapy

Dr Yea-Lih Lin, Institute of Human Genetics 


🕒 16.30 -17.00

Modulation of cancer cells antigenicity by radiation

Pr Sandra Demaria, Weill Cornell Medicine 

🕒 17.00 -17.30


Harnessing radiotherapy to boost the efficacy of cancer (immune)therapy

Dr Lorenzo Galluzzi, Weill Cornell Medicine 

Registration at www.immunorad.fr

🕒 17.30 -18.00

Tackling the immunosuppressive hypoxic tumor areas: a combinatorial approach

Dr Ludwig Dubois, Maastricht University 

18.00-21.00 COCKTAIL POSTER SESSION - part I

Wednesday September 15th 2021

MAIN PROGRAM


8.30-10.00 Session I

Radiation Response

(chair: David Raben and Michele Mondini)


🕒 8.30 -9.00

Normal tissue toxicity in the era of radiotherapy/immunotherapy combinations : preclinical challenges

Dr Agnès François, RSN 


🕒 9.00 -9.30

TRIM33 as a myeloid interferon checkpoint : from molecular mechanism to radiotherapy improvement

Dr Germain Rousselet, CEA 

🕒 9.30 -10.00

The microbiome impact on normal tissue radiation response

Dr Antonin Levy, Gustave Roussy 

10.00-10.30 Coffee break

10.30-12.30 Session II

Mutations

(chair: Marion Classe and Patricia Kannouche)


🕒 10.30 -11.00

New insights into the mutational processes and the landscape driver mutations of Basal Cell Carcinoma of skin from Whole Genome Sequencing

Dr Sergey Nikolaev, Gustave Roussy 

🕒 11.00 -11.30

Neutrophils hamper anti-PD-1 response in mismatch repair deficient tumors,

Dr Laetitia Nebot-Bral, Gustave Roussy 

🕒 11.30 -12.00

Mutational load and immunogenicity of gliomas

Dr Mehdi Touat, La Pitié Salpêtrière 

🕒 12.00 -12.30

Intercellular communication within the immune system

Pr Vassili Soumelis, IUH Saint-Louis 

🕒 Meet-the-Editor Session

Lorenzo Galluzzi, PhD 

Oncoimmunology, Editor-in-Chief

12.30-13.30 Lunch break and exhibition

14.00-16.00 Session III

Immune Contexture

(chair: Oliver Kepp and Charles-Antoine Dutertre)

🕒 14.00 -14.30

The immune contexture in the era of cancer immunotherapies

Dr Jerome Galon, Cordeliers Research Center 

🕒 14.30 -15.00

Immune signatures for characterization and prediction of responses of solid tumors to treatments with immune therapies and radiotherapy

Pr Udo Gaipl, Friedrich-Alexander University Erlangen-Nürnberg 


🕒 15.00 -15.30

Targeting lipid metabolism to generate anti-tumor immunity in irradiated glioblastoma

Dr Claire Vanpouille-Box, Weill Cornell Medicine 

🕒 15.30 -16.00

Can we predict response to immunotherapy in lung cancers?

Pr Fabrice Barlési, Gustave Roussy 

16.00-16.30 coffee break


16.30-18.30 Session IV

Cell Death and Dose Effect

(chair: Guido Kroemer and Jerome Galon)


🕒 16.30 -17.00

Ferroptosis and immunogenic cell death

Pr Peter Vandenabeele, Ghent University 


🕒 17.00 -17.30

Mobilizing anti-tumor immunity with low dose irradiation

Pr Fernanda Herrera, CHUV 


🕒 17.30 -18.00

Using low dose irradiation and nanoparticle to overcome checkpoint resistance

Pr James Welsh, MD Anderson Cancer Center 

🕒 18.00 -18.30

COVID-19- oncological specificities: what did we learn from virus-specific T cells responses for cancer?

Pr Laurence Zitvogel, Gustave Roussy 

Thursday September 16th 2021

8.30-10.00 Session V

Immunosuppression

(chair: George Coukos and Jean-Luc Perfettini)

🕒 8.30 -9.00

The role of cancer-associated fibroblasts and the extracellular matrix in the tumour response to radiotherapy

Dr Anna Wilkins, ICR 

🕒 9.00 -9.30

Elucidating the role of radiotherapy on macrophage-cancer cell crosstalk towards the development of novel immunomodulatory therapies

Dr Maria José Oliveira, University of Porto 

🕒 9.30 -10.00

Role of stromal heterogeneity in immunosuppression and immunotherapy resistance

Dr Fatima Mechta-Grigoriou, Institut Curie 

10.00-10.30 Coffee break


10.30-12.30 Session VI

Innate Immunity

(chair: Lorenzo Galluzzi and Alexandre Boissonas)


🕒 10.30 -11.00

Macrophage Ontogeny and Biology

Dr Florent Ginhoux, Gustave Roussy 


🕒 11.00 -11.30

Macrophage involvement in tissue responses to radiation in cancer and non-cancer pathologies

Dr Lydia Meziani, Gustave Roussy 


🕒 11.30 -12.00

Harnessing innate immunity in cancer therapy and beyond

Pr Eric Vivier, CIML 

🕒 12.00 -12.30

Targeting tumor-associated macrophages for cancer immunotherapy

Dr Jean-Luc Perfettini, Gustave Roussy 

12.30-14.00 Lunch break and exhibition


14.00-16.00 Session VII

Artificial Intelligence

(chair: Nikos Paragios and Stefan Michiels)


🕒 14.00 -14.30

Radiomics for predicting response to immunotherapy

Dr Roger Sun, Gustave Roussy 


🕒 14.30 -15.00

Machine Learning for radio-immunotherapy

Pr Issam El-Naqa, Moffit Cancer Center 


🕒 15.00 -15.30

AI and precision medicine in oncology

Pr Fabrice André, Gustave Roussy 

🕒 15.30 -16.00

Prospects for next generation radiotherapy at the era of AI and immunotherapy

Pr Eric Deutsch, Gustave Roussy 

16.00-16.30 Coffee break


16.30-18.00 Session VIII

Adaptive Immunity

(chair: Silvia Formenti and Judith Michels)


🕒 16.30 -17.00

Adoptive T cell therapy in solid tumors

Pr George Coukos, CHUV 


🕒 17.00 -17.30

Awaking immune system with radiation: bidirectional translational approach

Dr Maria Esperanza Rodriguez Ruiz, Clínica Universidad de Navarra 

🕒 17.30 -18.00

The 3Cs for Radioimmunotherapy: Combinatorial roadmaps, ctDNA and Courage (or common sense) in head and neck carcinoma

Pr David Raben, University of Colorado 

18.00 COCKTAIL POSTER SESSION - part II

8.30-10.00 Session IX

Immune Communication

(chair: Sandra Demaria and Anne-Gaelle Goubet)

⌚ 8.30 -9.00

Targeting IFN-I coupled innate immune receptors for cancer immunotherapy

Dr Hendrik Poeck, Technische Universität München 


⌚ 9.00 -9.30

The GOOD, the ELDER & the BAD: RNA Vaccine & Radiotherapy to fight Cancer

Dr Fulvia Vascotto, TrOn 

⌚ 9.30 -10.00

Unleashing the myeloid cell-dependent interferon response to improve the efficacy of radiotherapy in head and neck tumors, Dr

Michele Mondini, Gustave Roussy 

10.00-10.30 Coffee break

10.30-12.00 Session X

Immunogenicity

(chair: Jim Welsh and Jerome Durand-Labrunie)

⌚ 10.30 -11.00

Breaking through the resistance of HR+ breast cancer to immunotherapy

Dr Aitziber Buque, Weill Cornell Medicine 

⌚ 11.00 -11.30

Immunogenicity of particle therapy and the potential in combination with immunotherapy

Dr Alexander Helm, Technische Universität Darmstadt 

⌚ 11.30 -12.00

Strategies to enhance radiation immunogenicity

Pr Silvia Formenti, Weill Cornell Medicine 

Closing and Farewell:

Pr Silvia Formenti, Weill Cornell Medicine 

conference co-chair

Official Media Partner

THE LANCET
Oncology



**Weill Cornell
Medicine**



SOCRATE^{2.0}
Gustave Roussy Integrated Cancer Research

**GUSTAVE
ROUSSY**
CANCER CAMPUS
GRAND PARIS